In 2007, Takeda was one of Japan's leading pharmaceutical companies with sales mainly in Japan and the U.S., while Takeda takes the 15th place in global sales in the pharmaceutical market has been offset against the major industry consolidation. Yasuchika Hasegawa, president of Takeda, was concerned about the future of the company. To address the decline in the Japanese pharmaceutical market, Takeda expanded its business in overseas markets. But attempts by Takeda to become a global company, have been criticized as slow and not aggressive enough. One reason for this risk was Takeda's corporate culture. Worse, R & D pipeline Takeda was reduced, and patents on some of its main products were about to expire, which will inevitably lead to lower profits as generic drugs have entered the market. This case is a plan to convert Hasegawa Takeda pharmaceutical company in the world in a rapidly changing market. It covers the history Takeda, industry trends, and strategies for the acquisition Hasegawa. "Hide
by Charles O'Reilly, Asaka Ito, Hiromichi Kimura, Chris D Beaumont, Robert Kneller Source: Stanford Graduate School of Business 15 pages. Publication Date: January 17, 2012. Prod. #: OB83A-PDF-ENG
Related Case Solutions & Analyses:
Toledo Foundry
The Freelancers Union (B)
Erik Peterson at Biometra (A)
Codon Devices
Wal-Mart: Nonmarket Pressure and Reputation Risk (B)
General Managers Leadership Challenge: Building a Self-Renewing Institution
Black Caucus Groups at Xerox Corp. (A)
FX Risk Hedging at EADS
WBS project network
University of Trent
